127 related articles for article (PubMed ID: 8496926)
1. Synthesis of 2'-deoxyuridine and 5-fluoro-2'-deoxyuridine derivatives and evaluation in antibody targeting studies.
Henn TF; Garnett MC; Chhabra SR; Bycroft BW; Baldwin RW
J Med Chem; 1993 May; 36(11):1570-9. PubMed ID: 8496926
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of O-alkyl-3-N-aminoacyloxymethyl-5-fluoro-2'-deoxyuridine derivatives.
Harada N; Hongu M; Kawaguchi T; Ohohashi M; Oda K; Hashiyama T; Tsujihara K
Chem Pharm Bull (Tokyo); 1996 Jun; 44(6):1196-201. PubMed ID: 8814951
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
Kumar R; Xu LH; Knaus EE; Wiebe LI; Tovell DR; Tyrrell DL; Allen TM
J Med Chem; 1990 Feb; 33(2):717-23. PubMed ID: 2299637
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
Affleck K; Embleton MJ
Br J Cancer; 1992 Jun; 65(6):838-44. PubMed ID: 1616855
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
Freel Meyers CL; Hong L; Joswig C; Borch RF
J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
[TBL] [Abstract][Full Text] [Related]
7. 5-Hexyl-2'-deoxyuridine blocks the cytotoxic effects of 5-fluorodeoxyuridine or deoxyadenosine in leukemia L1210 cells in culture.
Cory JG; Halley MC; Jeney A; Lapis K
Cancer Res; 1990 Aug; 50(15):4552-6. PubMed ID: 2142444
[TBL] [Abstract][Full Text] [Related]
8. 3'-O- and 5'-O-Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis.
Baraniak D; Baranowski D; Ruszkowski P; Boryski J
Nucleosides Nucleotides Nucleic Acids; 2016; 35(4):178-94. PubMed ID: 26914155
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and physicochemical characteristics of a liver-targeted conjugate of fluorodeoxyuridine monophosphate with lactosaminated human albumin.
Di Stefano G; Tubaro M; Lanza M; Boga C; Fiume L; Traldi P
Rapid Commun Mass Spectrom; 2003; 17(22):2503-7. PubMed ID: 14608620
[TBL] [Abstract][Full Text] [Related]
10. In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates.
Goerlach A; Krauer KG; McKenzie IF; Pietersz GA
Bioconjug Chem; 1991; 2(2):96-101. PubMed ID: 1831049
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antiviral and cytotoxic activity of 2'-deoxyuridines, 2'-fluoro-2'-deoxyuridines and 2'-arabinouridines containing 5-(1-hydroxy-2-halo-2-ethoxycarbonylethyl)-, 5-(1-hydroxy-2-iodo-2- carboxyethyl)- and 5-[1-hydroxy (or methoxy)-2-iodoethyl] substituents.
Kumar R; Wiebe LI; Knaus EE; Allen TM; Tempest ML
Drug Des Discov; 1992 Feb; 8(3):179-89. PubMed ID: 1326340
[TBL] [Abstract][Full Text] [Related]
12. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Embleton MJ; Byers VS; Lee HM; Scannon P; Blackhall NW; Baldwin RW
Cancer Res; 1986 Nov; 46(11):5524-8. PubMed ID: 3489523
[TBL] [Abstract][Full Text] [Related]
14. 2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
Griengl H; Wanek E; Schwarz W; Streicher W; Rosenwirth B; De Clercq E
J Med Chem; 1987 Jul; 30(7):1199-204. PubMed ID: 3037079
[TBL] [Abstract][Full Text] [Related]
15. Experience in the preparation and experimental use of immunocytostatics.
Embleton MJ; Pimm MV; Garnett MC; Rowland GF; Simmonds RG; Baldwin RW
Behring Inst Mitt; 1984 May; (74):108-12. PubMed ID: 6591915
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36.
Pelham JM; Gray JD; Flannery GR; Pimm MV; Baldwin RW
Cancer Immunol Immunother; 1983; 15(3):210-6. PubMed ID: 6577942
[TBL] [Abstract][Full Text] [Related]
17. Conjugates of monoclonal antibody 791T/36 with methotrexate in cancer therapy.
Baldwin RW; Embleton MJ; Garnett MC; Pimm MV
NCI Monogr; 1987; (3):95-9. PubMed ID: 3469528
[TBL] [Abstract][Full Text] [Related]
18. An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines.
Garnett MC; Baldwin RW
Cancer Res; 1986 May; 46(5):2407-12. PubMed ID: 3457627
[TBL] [Abstract][Full Text] [Related]
19. 5-Alkynyl-2'-deoxyuridines: chromatography-free synthesis and cytotoxicity evaluation against human breast cancer cells.
Meneni S; Ott I; Sergeant CD; Sniady A; Gust R; Dembinski R
Bioorg Med Chem; 2007 Apr; 15(8):3082-8. PubMed ID: 17336074
[TBL] [Abstract][Full Text] [Related]
20. Antigenicity and drug susceptibility of human osteogenic sarcoma cells "escaping" a cytotoxic methotrexate-albumin-monoclonal antibody conjugate.
Embleton MJ; Garnett MC; Jacobs E; Baldwin RW
Br J Cancer; 1984 May; 49(5):559-65. PubMed ID: 6586198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
